CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Moderna will keep its COVID vaccine on the market at no cost to consumers, even after the federal government stops paying for it, the company announced Wednesday. "Everyone in the United States ...

Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its COVID-19 ...

Moderna is the second company to report encouraging results for its coronavirus vaccine candidate, saying its shot is 94.5% effective.

In the Moderna trial, 90 of the first 95 participants to develop COVID-19 had received the placebo and only five the active vaccine, so it was 94.5% effective.

In Moderna's first interim analysis, 95 people came down with COVID-19, 90 of whom received the placebo. Eleven people – all in the placebo group – developed "serious" cases of the disease.

Covid-19 can lead to a mild illness, or it can lead to a severe case that requires hospitalization and oxygen support. Of the 196 people who got sick in the Moderna study, 30 experienced severe ...